Algert Global LLC Decreases Holdings in Biohaven Ltd. (NYSE:BHVN)

Algert Global LLC decreased its holdings in Biohaven Ltd. (NYSE:BHVN) by 3.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 31,320 shares of the company’s stock after selling 1,072 shares during the period. Algert Global LLC’s holdings in Biohaven were worth $1,170,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BHVN. HighTower Advisors LLC boosted its position in Biohaven by 6.1% during the fourth quarter. HighTower Advisors LLC now owns 5,870 shares of the company’s stock valued at $219,000 after buying an additional 335 shares during the period. Franklin Resources Inc. lifted its stake in shares of Biohaven by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock valued at $4,206,000 after acquiring an additional 412 shares during the last quarter. FSC Wealth Advisors LLC boosted its holdings in Biohaven by 3.3% during the 4th quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company’s stock valued at $579,000 after acquiring an additional 500 shares during the period. Prudential Financial Inc. boosted its holdings in Biohaven by 9.4% during the 4th quarter. Prudential Financial Inc. now owns 5,980 shares of the company’s stock valued at $223,000 after acquiring an additional 514 shares during the period. Finally, Amalgamated Bank increased its stake in Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock worth $109,000 after purchasing an additional 527 shares during the period. Institutional investors own 88.78% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on BHVN shares. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $54.00 price target on shares of Biohaven in a report on Tuesday, March 4th. William Blair raised shares of Biohaven to a “strong-buy” rating in a research note on Thursday, April 24th. Robert W. Baird reduced their price target on Biohaven from $60.00 to $57.00 and set an “outperform” rating on the stock in a report on Monday, April 28th. Finally, Morgan Stanley dropped their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $62.54.

Biohaven Price Performance

Shares of NYSE BHVN opened at $20.20 on Friday. Biohaven Ltd. has a 1 year low of $15.79 and a 1 year high of $55.70. The firm has a 50-day moving average of $23.44 and a 200 day moving average of $35.36. The stock has a market cap of $2.06 billion, a P/E ratio of -2.16 and a beta of 1.18.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Biohaven

In other news, Director John W. Childs bought 32,700 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares of the company’s stock, valued at approximately $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.00% of the stock is owned by company insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.